Whitehawk Therapeutics (WHWK) Liabilities and Shareholders Equity (2010 - 2026)
Whitehawk Therapeutics (WHWK) reported Liabilities and Shareholders Equity of $127.2 million for Q1 2026, down 45.63% year-over-year from $234.0 million in Q1 2025, and down 15.65% on a QoQ basis from $150.8 million in Q4 2025.
Whitehawk Therapeutics (WHWK) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $127.2 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 45.63% year-over-year to $127.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $625.9 million (up 27.31% YoY) and the FY2025 annual result came in at $150.8 million, up 114.49% from the prior year.
- Liabilities and Shareholders Equity fell to $127.2 million in Q1 2026 per WHWK's latest filing, from $150.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $234.0 million in Q1 2025 and bottomed at $70.3 million in Q4 2024.
- The 5-year median for Liabilities and Shareholders Equity is $142.3 million (2022), against an average of $145.4 million.
- The widest annual swing landed in 2022, when Liabilities and Shareholders Equity surged 245.76%; it then sank 46.9% in 2024.
- Tracing WHWK's Liabilities and Shareholders Equity over 5 years: stood at $184.2 million in 2022, then fell by 28.12% to $132.4 million in 2023, then sank by 46.9% to $70.3 million in 2024, then soared by 114.49% to $150.8 million in 2025, then decreased by 15.65% to $127.2 million in 2026.
- Per Business Quant, the three latest WHWK Liabilities and Shareholders Equity figures stand at $127.2 million (Q1 2026), $150.8 million (Q4 2025), and $167.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | 127.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127.23 Mn |
| Dec 31, 2025 | 150.83 Mn |
| Sep 30, 2025 | 167.02 Mn |
| Jun 30, 2025 | 180.82 Mn |
| Mar 31, 2025 | 234.00 Mn |
| Dec 31, 2024 | 70.32 Mn |
| Sep 30, 2024 | 85.70 Mn |
| Jun 30, 2024 | 101.62 Mn |
| Mar 31, 2024 | 111.07 Mn |
| Dec 31, 2023 | 132.42 Mn |
| Sep 30, 2023 | 139.66 Mn |
| Jun 30, 2023 | 151.23 Mn |
| Mar 31, 2023 | 170.65 Mn |
| Dec 31, 2022 | 184.24 Mn |
| Sep 30, 2022 | 194.10 Mn |
| Jun 30, 2022 | 128.64 Mn |
| Mar 31, 2022 | 142.32 Mn |
| Dec 31, 2021 | 157.91 Mn |
| Sep 30, 2021 | 168.77 Mn |
| Jun 30, 2021 | 37.42 Mn |
| Mar 31, 2021 | 41.16 Mn |
| Dec 31, 2020 | 18.83 Mn |
| Sep 30, 2020 | 49.83 Mn |
| Jun 30, 2020 | 45.72 Mn |
| Mar 31, 2020 | 35.70 Mn |
| Dec 31, 2019 | 39.94 Mn |
| Sep 30, 2019 | 45.55 Mn |
| Jun 30, 2019 | 49.60 Mn |
| Mar 31, 2019 | 55.06 Mn |
| Dec 31, 2018 | 64.12 Mn |
| Sep 30, 2018 | 70.16 Mn |
| Jun 30, 2018 | 69.54 Mn |
| Mar 31, 2018 | 14.73 Mn |
| Dec 31, 2017 | 21.03 Mn |
| Sep 30, 2017 | 26.00 Mn |
| Jun 30, 2017 | 29.79 Mn |
| Mar 31, 2017 | 36.28 Mn |
| Dec 31, 2016 | 2.40 Mn |
| Sep 30, 2016 | 7,837.00 |
| Jun 30, 2016 | 20,279.00 |
| Mar 31, 2016 | 13,229.00 |
| Dec 31, 2015 | 18,529.00 |
| Sep 30, 2015 | 6,270.00 |
| Jun 30, 2015 | 10,095.00 |
| Mar 31, 2015 | 23,287.00 |
| Dec 31, 2014 | 5,263.00 |
| Sep 30, 2014 | 17,868.00 |
| Jun 30, 2014 | 4,568.00 |
| Mar 31, 2014 | 6,508.00 |
| Dec 31, 2013 | 8,783.00 |
| Sep 30, 2013 | 14,670.00 |
| Jun 30, 2013 | 18,420.00 |
| Mar 31, 2013 | 3,831.00 |
| Dec 31, 2012 | 8,107.00 |
| Sep 30, 2012 | 11,266.00 |
| Jun 30, 2012 | 15,561.00 |
| Mar 31, 2012 | 24,223.00 |
| Dec 31, 2011 | 6,625.00 |
| Sep 30, 2011 | 10,505.00 |
| Jun 30, 2011 | 15,480.00 |
| Dec 31, 2010 | 29,398.00 |